| 埃克替尼对非小细胞肺癌EGFR 21外显子少见突变的临床疗效 |
| |
| 引用本文： | 黄章洲,陈燕坪,庄武,黄韵坚,朱有才,杜开齐,方美玉,王晓江,师怡,林贤东,许春伟,陈刚.埃克替尼对非小细胞肺癌EGFR 21外显子少见突变的临床疗效[J].国际病理科学与临床杂志,2017,37(3). |
| |
| 作者姓名： | 黄章洲 陈燕坪 庄武 黄韵坚 朱有才 杜开齐 方美玉 王晓江 师怡 林贤东 许春伟 陈刚 |
| |
| 作者单位： | 1. 福建医科大学附属福建省肿瘤医院胸部肿瘤内科,福州,350014;2. 福建医科大学附属福建省肿瘤医院病理科,福州,350014;3. 浙江省荣军医院胸部疾病中心,浙江 嘉兴,314000;4. 浙江省肿瘤医院综合肿瘤内科,杭州,310022 |
| |
| 基金项目： | 国家临床重点专科建设项目，福建省科技厅引导性项目，福建省科技厅引导性项目，浙江省卫生科研计划基金，浙江省中医药局科研基金，浙江省科技厅公益类科研计划 (2015C33194).This work was supported by National Clinical Key Specialty Construction Program，Leading Project Foundation of Science Department of Fujian Province，Leading Project Foundation of Science Department of Fujian Province，Medical Scientific Research Foundation of Zhejiang Province of China，Zhejiang Administration of Traditional Chinese Medicine Foundation，the Science and Technology Planning Project of Zhejiang Province of China |
| |
| 摘 要： | 目的:探讨埃克替尼对非小细胞肺癌(non-small cell lung cancer,NSCLC)EGFR 21外显子L861Q/L833F突变的临床疗效.方法:回顾性分析17例埃克替尼治疗EGFR 21外显子少见突变的NSCLC,服用至病情进展或出现不可耐受的毒副作用,并观察疗效.结果:17例L861Q/L833F突变患者中L861Q突变17例,中位生存时间2.2个月,L833F突变1例,中位生存时间4.2个月.L833F突变患者生存时间稍长.复合突变与单纯突变相比,复合突变中位生存时间更长(L861Q突变2.1个月vs.5.6个月,P=0.065).结论:埃克替尼在EGFR基因21外显子少见突变的疗效上比传统敏感突变未见明显优势,但复合突变比单纯突变临床获益更多.
|
| 关 键 词： | 非小细胞肺癌 埃克替尼 21外显子 |
Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 21 rare mutations |
| |
| HUANG Zhangzhou,CHEN Yanping,ZHUANG Wu,HUANG Yunjian,ZHU Youcai,DU Kaiqi,FANG Meiyu,WANG Xiaojiang,SHI Yi,LIN Xiandong,XU Chunwei,CHEN Gang.Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 21 rare mutations[J].Journal of International Pathology and Clinical Medicine,2017,37(3). |
| |
| Authors: | HUANG Zhangzhou CHEN Yanping ZHUANG Wu HUANG Yunjian ZHU Youcai DU Kaiqi FANG Meiyu WANG Xiaojiang SHI Yi LIN Xiandong XU Chunwei CHEN Gang |
| |
| Abstract: | Objective: To investigate the efficacy of icotinib in patients with non-small cell lung cancer (NSCLC) that carrying L861Q/L833F in EGFR exon 21. Methods: We retrospectively analysed 17 cases of EGFR 21 exon rare mutation NSCLC patients until the progress of the disease or the emergence of the side effects, and clinical efficacy was observed after months followed-up. Results: Seventeen patients with L861Q/L833F mutations were enrolled. Mutations including L861Q and L833F mutations were observed in 17 and 1 patients, respectively. In total, the median progression-free survival (PFS) were 2.2 months, respectively. Patients with L833F mutation manifested the longest median PFS (4.2 months), followed by those with L861Q (2.2 months). Patients with complex mutations show a better PFS than those with single mutations (L861Q mutations 2.1 months vs. 5.6 months, P=0.065). Conclusion: Icotinib is less effective in patients with exon 21 uncommon mutations than in those with common mutations. Patients with complex mutations benefited more from icotinib than those with single mutations. |
| |
| Keywords: | non-small-cell lung cancer icotinib exon 21 |
| 本文献已被 万方数据 等数据库收录！ |
|
